Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 4/20 | 0.46 |
| ▸ | BCR | P11274 | 4/20 | 0.46 |
| ▸ | EGFR | P00533 | 5/20 | 0.45 |
| ▸ | SYK | P43405 | 3/20 | 0.44 |
| ▸ | AXL | P30530 | 2/20 | 0.43 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449787 | 0.90 | ALK (0.54) | ABL1BCREGFRSYKALK | |
| SCHEMBL3450288 | 0.86 | ABL1 (0.46) | ABL1BCREGFRSYKAXL | |
| SCHEMBL3450587 | 0.85 | CCND3 (0.51) | ABL1BCREGFRSYKAXL | |
| SCHEMBL3449451 | 0.84 | AXL (0.57) | EGFRAXLALKMAPK1 | |
| SCHEMBL13348309 | 0.84 | SYK (0.44) | ABL1BCREGFRSYKAXL | |
| SCHEMBL3452720 | 0.83 | MAPK1 (0.51) | EGFRAXLMAPK1 | |
| SCHEMBL3449764 | 0.83 | MAPK1 (0.51) | EGFRAXLMAPK1 | |
| SCHEMBL3449638 | 0.82 | MAPK1 (0.50) | EGFRAXLMAPK1 | |
| SCHEMBL3450023 | 0.82 | MAPK1 (0.50) | EGFRAXLMAPK1 | |
| SCHEMBL3344452 | 0.82 | ABL1 (0.56) | ABL1BCREGFRSYKAXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | ASTRAZENECA AB | 2010-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137313-A1 | HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF | SDHA, SDHB, UROD | ABL1 370/4885BCR 3224/4885EGFR 2771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.